SCHEMBL87458

SCHEMBL87458

CC(F)(F)CC(F)(F)CC(F)(F)CC(F)(F)CCCCCC(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.43
LMNA P02545 3/20 0.43
NFKB1 P19838 1/20 0.43
PMP22 Q01453 1/20 0.43
GPR84 Q9NQS5 7/20 0.41
PPARG P37231 7/20 0.41
PPARD Q03181 7/20 0.41
PPARA Q07869 7/20 0.41
HDAC11 Q96DB2 5/20 0.41
PTPN1 P18031 3/20 0.41
TDP1 Q9NUW8 3/20 0.41
ALDH1A1 P00352 2/20 0.41
TLR2 O60603 2/20 0.41
FABP4 P15090 2/20 0.41
FFAR1 O14842 2/20 0.41
ALOX15 P16050 2/20 0.41
HSD17B10 Q99714 2/20 0.41
SLC22A6 Q4U2R8 1/20 0.41
SLC22A8 Q8TCC7 1/20 0.41
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL87457 0.85 NAALAD2 (0.38) TSHRLMNATDP1ALDH1A1FFAR1
SCHEMBL16302334 0.81 TSHR (0.55) TSHRLMNANFKB1PMP22GPR84
SCHEMBL1223994 0.78 LMNA (0.52) TSHRLMNANFKB1PMP22GPR84
SCHEMBL87467 0.75 LPAR1 (0.44) TSHRHSD17B10MEN1KMT2ACYP1A2
SCHEMBL11096370 0.72 TSHR (0.55) TSHRLMNANFKB1PMP22GPR84
SCHEMBL15130876 0.72 HMGCR (0.42) TSHRTDP1ALDH1A1FFAR1CPT2
SCHEMBL25307961 0.72 TSHR (0.60) TSHRLMNANFKB1PMP22GPR84
SCHEMBL7813622 0.72 TSHR (0.60) TSHRLMNANFKB1PMP22GPR84
SCHEMBL10442148 0.72 TSHR (0.60) TSHRLMNANFKB1PMP22GPR84
SCHEMBL5249605 0.72 TSHR (0.60) TSHRLMNANFKB1PMP22GPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230173076-A1 METABOLICALLY STABLE PEPTIDE ANALOGS UNIV STRASBOURG (FR) 2023-06-08 US disclosed
US-20170355734-A1 Metabolically Stable Apelin Analogs in the Treatment of Disease Mediated by the Apelin Receptor UNIVERSITE DE STRASBOURG (FR) 2017-12-14 US disclosed
US-20150112042-A1 Antigen Delivery Vectors and Constructs ALTIMMUNE UK LIMITED (GB) 2015-04-23 US disclosed
US-8759281-B2 Antigen delivery vectors and constructs IMMUNE TARGETING SYSTEMS LTD. (GB) 2014-06-24 US disclosed
US-20120315293-A1 Antigen Delivery Vectors and Constructs IMMUNE TARGETING SYSTEMS LTD. 2012-12-13 US disclosed
US-8129333-B2 Antigen delivery vectors and constructs IMMUNE TARGETING SYSTEMS LTD. (GB) 2012-03-06 US disclosed
US-20120034259-A1 ANTIGEN DELIVERY VECTORS AND CONSTRUCTS ALTIMMUNE UK LIMITED (GB) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150112042-A1 Antigen Delivery Vectors and Constructs LY96, CD74, CD69 TSHR 3438/4885LMNA 4002/4885NFKB1 681/4885
US-20120315293-A1 Antigen Delivery Vectors and Constructs LY96, CD74, CD69 TSHR 3438/4885LMNA 4002/4885NFKB1 681/4885
US-20170355734-A1 Metabolically Stable Apelin Analogs in the Treatment of Disease Mediated by the Apelin Receptor APLNR, AVPR2, AVPR1A TSHR 297/4885LMNA 2310/4885NFKB1 2735/4885
US-20230173076-A1 METABOLICALLY STABLE PEPTIDE ANALOGS GPR119, GLP1R, GIPR TSHR 346/4885LMNA 4537/4885NFKB1 4262/4885
US-20120034259-A1 ANTIGEN DELIVERY VECTORS AND CONSTRUCTS LY96, CD74, CD69 TSHR 3438/4885LMNA 4002/4885NFKB1 681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.